Hims vs Novo Nordisk, Running vs at-home fitness, Women's performance research scores $50M
February 6, 2026: Your daily rundown of health and wellness news, in under 5 minutes.
Today's top stories:
Hims launches compounded GLP-1 pill starting at $49/month as needle-free alternative, but Novo Nordisk threatens legal action over what it calls illegal compounding
Women's Health, Sports, and Performance Medical Institute launches with $50M+ to fund injury prevention research for female athletes
Peloton reports Q2 revenue of $656.5M missing expectations with paid subscribers down 7% year-over-year, while Brooks reports revenue up 16% marking ninth straight year of growth
More from Fitt…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.